Parkinson's disease (PD) is the most common degenerative Parkinson's syndrome and is linked, among other things, to the excessive accumulation of an abnormally aggregating protein, alpha-synuclein. Progressive Supranuclear Palsy (PSP) is another Parkinson's syndrome, linked, among other things, to the abnormal accumulation of the protein Tau, and expressed clinically by falls, early cognitive impairment and oculomotor disorders, not present in PD. The onset of these disorders is so gradual that differential diagnosis between the two diseases is only possible at a late stage, on average 3 to 5 years after the onset of symptoms. To date, there is a lack of validated imaging biomarkers for diagnosing and monitoring PD and PSP. There is therefore an urgent need for the development of robust biomarkers capable of detecting neurodegeneration at an early stage, in order to aid differential diagnosis as soon as symptoms appear, and to potentially enable these patients to be included in specific therapeutic trials (as these diseases are pathophysiologically different) with potential neuroprotective effects. The development of cutting-edge technologies such as 7T MRI, combined with optimized image processing methods, now enable non-invasive in vivo exploration and analysis of these small structures in terms of ion homeostasis (sodium), microstructure (volumetry, amount of iron and neuromelanin) and connectivity.
Study Type
INTERVENTIONAL
Allocation
NON_RANDOMIZED
Purpose
DIAGNOSTIC
Masking
NONE
Enrollment
63
Patients will have a 7T MRI and questionnaires
Ch Pays D'Aix
Aix-en-Provence, France
Hôpital Privé La Casamance - Service de Neurologie
Aubagne, France
Centre Hospitalier Avignon - Service de Neurologie
Avignon, France
CENTRE HOSPITALIER UNIVERSITAIRE NICE - Service de Neurologie
Nice, France
CENTRE HOSPITALIER NIMES - Service de Neurologie
Nîmes, France
CENTRE HOSPITALIER SAINTE MUSSE - Toulon
Toulon, France
Sodium accumulation between Parkinson disease patients and Progressive Supranuclear Palsy
Comparison of intracerebral sodium accumulation measured by very high-field (7T) cerebral MRI between subjects with Idiopathic Parkinson's Disease and subjects with early-stage Progressive Supra-Nuclear Palsy
Time frame: Between month 0 and month 3 after inclusion
Sodium accumulation between Parkinson disease patients (MPI) and control subjects
Comparison of intracerebral sodium accumulation between subjects with early-stage Parkinson's Disease (PD) and control subjects.
Time frame: Between month 0 and month 3 after inclusion
Sodium accumulation between Progressive Supra-nuclear patients (soPSP) and control subjects
Comparison of intracerebral sodium accumulation between subjects with soPSP and control subjects.
Time frame: Between month 0 and month 3 after inclusion
Brain atrophy between MPI and soPSP patients
3D mapping of brain atrophy differences measured in Voxel Based Morphometry (VBM), value in cm3
Time frame: Between month 0 and month 3 after inclusion
Brain atrophy between MPI and control group
3D mapping of brain atrophy differences measured in Voxel Based Morphometry (VBM), value in cm3
Time frame: Between month 0 and month 3 after inclusion
Brain atrophy between soPSP and control group
3D mapping of brain atrophy differences measured in Voxel Based Morphometry (VBM), value in cm3
Time frame: Between month 0 and month 3 after inclusion
Iron accumulation between soPSP and control group
3D mapping of iron accumulation differences measured by Quantitative Susceptibility Mapping (QSM), values in ppm
Time frame: Between month 0 and month 3 after inclusion
Iron accumulation between MPI and soPSP patients
3D mapping of iron accumulation differences measured by Quantitative Susceptibility Mapping (QSM), values in ppm
Time frame: Between month 0 and month 3 after inclusion
Iron accumulation between soPSP patients and control group
3D mapping of iron accumulation differences measured by Quantitative Susceptibility Mapping (QSM), values in ppm
Time frame: Between month 0 and month 3 after inclusion
Accumulation of neuromelanin between MPI and soPSP patients
3D mapping of neuromelanin differences (signal/MT ratio)
Time frame: Between month 0 and month 3 after inclusion
Accumulation of neuromelanin between MPI patients and control group
3D mapping of neuromelanin differences (signal/MT ratio)
Time frame: Between month 0 and month 3 after inclusion
Accumulation of neuromelanin between soPSP patients and control group
3D mapping of neuromelanin differences (signal/MT ratio)
Time frame: Between month 0 and month 3 after inclusion
Movement of water molecules between MPI and soPSP patients
3D mapping of differences in mean diffusivity (DM), values in mm2/s
Time frame: Between month 0 and month 3 after inclusion
Movement of water molecules between MPI patients and control group
3D mapping of differences in mean diffusivity (DM), values in mm2/s
Time frame: Between month 0 and month 3 after inclusion
Movement of water molecules between soPSP patients and control group
3D mapping of differences in mean diffusivity (DM), values in mm2/s
Time frame: Between month 0 and month 3 after inclusion
Structural connectivity between MPI and soPSP patients
3D mapping of anisotropy fraction (AF) differences, values between 0 and 1
Time frame: Between month 0 and month 3 after inclusion
Structural connectivity between soPSP patients and control group
3D mapping of anisotropy fraction (AF) differences, values between 0 and 1
Time frame: Between month 0 and month 3 after inclusion
Structural connectivity between MPI patients and control group
3D mapping of anisotropy fraction (AF) differences, values between 0 and 1
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and age
Correlation between sodium concentration (mmol/L) and age
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and sex
Correlation between sodium concentration (mmol/L) and sex
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and laterality
Correlation between sodium concentration (mmol/L) and laterality
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and sex
Measure by Voxel Based Morphometry (VBM) in cm3 and sex
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and age
Measure by Voxel Based Morphometry (VBM) in cm3 and age
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and laterality
Measure by Voxel Based Morphometry (VBM) in cm3 and laterality
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and age
Measure by Quantitative Susceptibility Mapping (QSM) in ppm and age
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and sex
Measure by Quantitative Susceptibility Mapping (QSM) in ppm and sex
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and laterality
Measure by Quantitative Susceptibility Mapping (QSM) in ppm and laterality
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and age
Correlation between ratio of signal/MT and age
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and sex
Correlation between ratio of signal/MT and sex
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and laterality
Correlation between ratio of signal/MT and laterality
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and age
Correlation between anisotropy fraction (AF) and age
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and sex
Correlation between anisotropy fraction (AF) and sex
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and laterality
Correlation between anisotropy fraction (AF) and laterality
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and duration of disease progression
Correlation between anisotropy fraction (AF) and duration of the disease
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and duration of disease progression
Correlation between ratio of signal/MT and duration of the disease
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and duration of disease progression
Measure by Quantitative Susceptibility Mapping (QSM) in ppm and duration of the disease
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and duration of disease progression
Measure by Voxel Based Morphometry (VBM) in cm3 and duration of disease progression
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and duration of disease progression
Correlation between sodium concentration (mmol/L) and duration of disease
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and sense of smell
Correlation between sodium concentration (mmol/L) and sense of smell (questionnaire)
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and sense of smell
Measure by Voxel Based Morphometry (VBM) in cm3 and sense of smell (questionnaire)
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and sense of smell
Measure by Quantitative Susceptibility Mapping (QSM) in ppm and sense of smell (questionnaire)
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and sense of smell
Correlation between ratio of signal/MT and sense of smell (questionnaire)
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and sense of smell
Correlation between anisotropy fraction (AF) and sense of smell (questionnaire)
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and severity of disease
Unified Parkinson's Disease Rating Scale (UPDRS), 0 to 199, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and quality of life
Schwab \& England score, 0 to 100%, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and quality of life
Schwab \& England score, 0 to 100%, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and quality of life
Schwab \& England score, 0 to 100%, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and quality of life
Schwab \& England score, 0 to 100%, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and quality of life
Correlation between Schwab \& England score (Schwab \& England score, 0 to 100%, 0 means better outcome) and sodium concentration (mmol/L)
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and severity of disease
Unified Parkinson's Disease Rating Scale (UPDRS), 0 to 199, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and severity of disease
Unified Parkinson's Disease Rating Scale (UPDRS), 0 to 199, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and severity of disease
Unified Parkinson's Disease Rating Scale (UPDRS), 0 to 199, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and Hospital Anxiety and Depression
HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and Hospital Anxiety and Depression
HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and Hospital Anxiety and Depression
HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and Hospital Anxiety and Depression
HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and Hospital Anxiety and Depression
HAD Echelle (Hospital Anxiety and Depression), 0 to 3, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and Sleep Behavior Disorder
REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and Sleep Behavior Disorder
REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and Sleep Behavior Disorder
REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and Sleep Behavior Disorder
REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and Sleep Behavior Disorder
REM Sleep Behavior Disorder Screening Questionnaire, 0 to 13, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and motivation scale
Starkstein motivation scale, 0 to 42, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and motivation scale
Starkstein motivation scale, 0 to 42, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and motivation scale
Starkstein motivation scale, 0 to 42, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and motivation scale
Starkstein motivation scale, 0 to 42, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and motivation scale
Starkstein motivation scale, 0 to 42, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and non-motor fluctuations
Number of non-motor fluctuations
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and non-motor fluctuations
Number of non-motor fluctuations
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and non-motor fluctuations
Number of non-motor fluctuations
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and non-motor fluctuations
Number of non-motor fluctuations
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and non-motor fluctuations
Number of non-motor fluctuations
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and cognitives functions
Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and cognitives functions
Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and cognitives functions
Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and cognitives functions
Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and cognitives functions
Score Montreal Cognitive Assessment (MoCA), 0 to 30, 0 means worse outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and quality of life
Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and quality of life
Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and quality of life
Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and quality of life
Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and quality of life
Parkinson's Disease Questionnaire (PDQ 39), 0 to 156, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and hypotension
Blood pressure test for orthostatic hypotension
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and hypotension
Blood pressure test for orthostatic hypotension
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and hypotension
Blood pressure test for orthostatic hypotension
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and hypotension
Blood pressure test for orthostatic hypotension
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and hypotension
Blood pressure test for orthostatic hypotension
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between structural connectivity and hallucinations
Miami Questionnaire, 0 to 70, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between accumulation of neuromelanin and hallucinations
Miami Questionnaire, 0 to 70, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between iron accumulation and hallucinations
Miami Questionnaire, 0 to 70, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between brain atrophy and hallucinations
Miami Questionnaire, 0 to 70, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
Measurement of the dependency between sodium accumulation and hallucinations
Miami Questionnaire, 0 to 70, 0 means better outcome
Time frame: Between month 0 and month 3 after inclusion
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.